Targets › CD1D
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Apr 2028.
Antigen-presenting protein that binds self and non-self glycolipids and presents them to T-cell receptors on natural killer T-cells. (UniProt, P15813)
Open in Phaseline: the race on CD1D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BioPhoenix | BPC-2001 Invariant natural killer T (iNKT) cell activator | CD1D | Phase 2 | Graft -Versus-host-disease | Apr 2028 |
Graft -Versus-host-disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.